For pathology, the mean survival and progression-free time of the astrocytoma, WHO grade 4, IDH mutation subgroup were 21.355 ± 1.025 months (95% CI: 19.346–23.365 months) and 14.806 ± 0.974 months (95% CI: 12.898–16.715 months), respectively, whereas the mean survival and progression-free time of the glioblastoma subgroup were 17.033 ± 0.467 months (95% CI: 16.118–17.947 months) and 11.817 ± 0.393 months (95% CI: 11.046–12.587 months), respectively. Here, IDH1 is linked to astrocytoma (excluding glioblastoma).